CRISPR Mutagenesis of BBL Nucleic Acids for Nicotine Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively modulate nicotine biosynthesis in tobacco plants, leading to high nicotine levels that contribute to addiction and the formation of carcinogenic tobacco-specific nitrosamines, necessitating a solution to reduce nicotine content in tobacco products.
Innovation Solution
Introduction of mutations in specific berberine bridge enzyme-like nucleic acids (BBLe, BBLd-1, and BBLd-2) within Nicotiana plants to decrease nicotinic alkaloid production, using techniques such as CRISPR-Cas nucleases to alter gene expression and reduce nicotine content.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional breeding or chemical treatment methods are used to reduce nicotine levels, then nicotine content may be reduced, but the methods are ineffective or fail to achieve significant reduction
Solution Approach 1:
The patent applies parameter changes by modifying the nucleotide sequences of BBL genes (BBLe, BBLd-1, BBLd-2) to alter their expression levels and enzymatic activity. By changing the genetic parameters through mutations, deletions, or substitutions in the coding regions, the patent achieves significant reduction in nicotine content that conventional methods cannot accomplish.
Solution Approach 2:
The patent replaces mechanical or chemical methods with a biological/genetic mechanism. Instead of using physical breeding techniques or chemical treatments, the invention uses CRISPR-Cas nucleases and other genome editing tools to directly modify the DNA sequences of BBL genes, thereby achieving precise and effective control over nicotine biosynthesis.
2Object-affected harmful factors
If nicotine levels are reduced to below critical threshold, then addiction response is eliminated, but current methods cannot reliably achieve this threshold
Solution Approach 1:
The patent uses parameter changes in the genetic sequence to precisely control nicotine levels. By introducing specific mutations in the BBL genes that encode key enzymes in the nicotine biosynthesis pathway, the patent can accurately adjust enzyme activity to maintain nicotine levels below the addiction threshold while preserving other plant qualities.
Solution Approach 2:
The patent employs feedback mechanisms through the use of selectable markers and screening methods to identify and select plants that have achieved the desired nicotine reduction. The genome editing process includes verification steps to ensure that the nicotine levels are reduced to the target threshold, providing feedback control over the precision of nicotine level management.
3Quantity of substance
If BBL genes are mutated to reduce nicotine, then nicotinic alkaloid production decreases, but may affect other plant qualities
Solution Approach 1:
The patent applies local quality by specifically targeting and modifying only the BBL genes (BBLe, BBLd-1, BBLd-2) involved in nicotine biosynthesis, while leaving the rest of the plant genome unchanged. This localized genetic modification approach reduces nicotinic alkaloid content without affecting other plant qualities, as the mutations are confined to specific gene regions that control alkaloid production.
Solution Approach 2:
The patent segments the nicotine biosynthesis pathway by targeting specific BBL genes individually. By creating separate mutation events in BBLe, BBLd-1, and BBLd-2 genes, the patent can selectively reduce nicotine production while maintaining the functionality of other metabolic pathways and plant traits through independent gene modification.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach results in Nicotiana plants with significantly reduced nicotine levels, thereby decreasing the formation of carcinogenic tobacco-specific nitrosamines and aiding in smoking cessation, while maintaining desirable plant qualities.
Implementation Method 1
using techniques such as CRISPR-Cas nucleases to alter gene expression and reduce nicotine content
Data Source
AI summary
The present invention relates to modifications of berberine bridge enzyme-like nucleic acids and their use in modulation of nicotine biosynthesis in plants.